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Matthias Niedrig11, Mark Brönstrup  2,3, Hans-Joachim Fritz12 & Ahmed Abd el Wahed1
Zika virus (ZIKV) is a mosquito-borne flavivirus. Homologous proteins of different flaviviruses display 
high degrees of sequence identity, especially within subgroups. this leads to extensive immunological 
cross-reactivity and corresponding problems for developing a ZIKV-specific serological assay. In this 
study, peptide microarrays were employed to identify individual ZIKV antibody targets with promise 
in differential diagnosis. A total of 1643 overlapping oligopeptides were synthesized and printed onto 
glass slides. together, they encompass the full amino acid sequences of ZIKV proteomes of African, 
Brazilian, UsA, and French polynesian origins. the resulting ZIKV scanning microarray chips were used 
to screen three pools of sera from recent Zika outbreaks in senegal and Cape Verde, in Brazil, and from 
overseas travelers returning to the eU. together with a mixed pool of well characterized, archived sera 
of patients suffering from infections by dengue, yellow fever, tick-borne encephalitis, and West Nile 
viruses, a total of 42 sera went into the study. Sixty-eight antibody target regions were identified. Most 
of which were hitherto unknown. Alignments and sequence comparisons revealed 13 of which could be 
classified as bona fide ZIKV-specific. These identified antibody target regions constitute a founding set 
of analytical tools for serological discrimination of ZIKV from other flaviviruses.
Zika virus (ZIKV), a mosquito-borne flavivirus, was first isolated from sentinel Rhesus macaques in the Zika 
forest of Uganda in 19471. The first human case was recorded in Nigeria in 1954. Before 2007, many small-scale 
epidemics were recorded in Africa and Asia2. Yap island (Micronesia) was the first area outside Africa and Asia to 
confirm human ZIKV infection3. Around one-tenth of the population of French Polynesia encountered the infec-
tion during the 2013 outbreak4. In 2015, the Brazilian ministry of health estimated around 440,000 to 1,300,000 
individuals in Brazil that may have contracted the infection. The potential of ZIKV spreading to other countries 
is high with almost one-fourth of the human population worldwide being at risk of encountering ZIKV infection. 
In regions like Europe, ZIKV transmission risk is present through high mobility and global connectivity5.
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Clinical signs of ZIKV infection are ranging from asymptomatic to mild headaches, fever, skin rashes and joint 
pain, which usually last a few days. The symptoms are unspecific and are frequently misdiagnosed as caused by 
dengue or chikungunya virus6. ZIKV is transmitted mainly by Aedes mosquitoes. Many reports discuss two addi-
tional ZIKV infection pathways: sexual intercourse and from a pregnant woman to her fetus7,8. ZIKV RNA was 
detected in the amniotic fluid of a pregnant woman9 and in the brain of an aborted fetus afflicted with microceph-
aly10. Moreover, ZIKV was linked to increased numbers of Guillian-Barré Syndrome cases in affected countries11.
ZIKV RNA can be detected in blood and saliva during the first five days of onset of symptoms, up to 21 days 
in urine and for up to one year in semen12–15. Longer persistence of anti-ZIKV antibodies in serum (IgM: up to 
two months; IgG: two years)16,17 extends the practicable diagnostic time window. On the other hand, high degrees 
of sequence identity of homologous proteins and concomitant immunological cross-reactivity among all flavi-
viruses, in particular within the various subgroups, have been reported18,19. These facts profoundly complicate 
serological diagnosis, especially in areas, where ZIKV and dengue virus are co-circulating and/or yellow fever 
vaccine is applied routinely20,21. Still, serological differentiation of ZIKV from other flaviviruses remains desirable 
and some progress towards resolving the difficulties has been announced22–24. This present study introduces a 
new approach resting on the identification, in larger numbers, of ZIKV-specific antibody targets. Specifically, 
we report comparative deconvolution of complex B cell responses against ZIKV and other flavivirus by screen-
ing corresponding sera with a microarray chip made up of overlapping peptides covering the entire amino acid 
sequence of the ZIKV genomic polyprotein. As a result, 13 short linear stretches of polypeptide sequence, scat-
tered throughout the viral proteome, were identified that exhibit exclusive reactivity towards ZIKV antisera.
Results
A (series of) positive array spot(s) indicates an antibody target and positions it within a protein sequence. In the 
context of the overlapping peptides method, the term ‘antibody target’ denotes a stretch of polypeptide chain of an 
antigen encompassing either a single linear B cell epitope or a locally clustered set thereof. In the latter case, it is 
called an antibody target region (ATR)25. Since a spots series as such often does not allow distinguishing between 
single epitope and ATR, the latter term is occasionally also used as a synonym of the generic name “antibody 
target” with epitopes regarded as extreme cases within that class.
Compiling a comprehensive list of antibody targets (epitopes, ATRs) participating in B cell responses to ZIKV 
infection and singling out from it the ZIKV-specific subset will, so the working hypothesis, enable diagnosis of 
ZIKV infection against a background of extensively cross-reacting other flaviviruses (e.g. dengue, yellow fever, 
tick-borne encephalitis, and West Nile virus). As shown earlier25, the necessary deconvolution of complex B cell 
responses to the level of contributions made by individual short stretches of polypeptide chain can be achieved 
experimentally by peptide microarray techniques. Comparing ATRs resulting from inspection of ZIKV and 
non-ZIKV flaviviral antisera will reduce the former to the ZIKV-specific subset. From this, discriminating immu-
nochemical reagents can be derived.
Immunochemical experiments. Three pools of sera from ZIKV-infected individuals and one mixed pool 
of anti-flavivirus sera were prepared and screened for serological footprints (separate experiments for IgM and 
IgG) employing peptide microarray chips (Fig. 1). Two sets of original data are displayed in Fig. 2. Positively 
responding array spots (Fig. 1) delineate antibody targets (white and blue frames in Fig. 2).
ATRs identified: Overview and crude classification. The experiments uncovered 68 ATRs, most of 
which were hitherto unknown. Of these, 21 were recognized by both IgM and IgG, 30 by IgM alone and 17 by 
IgG alone (Figs 2–4 and Supplementary Table S1). The targets are scattered across the entire proteome with no 
striking preference of envelope over non-envelope proteins (Fig. 3). From antibodies directed against the latter, 
no contribution to virus neutralization would be expected, but in the context of diagnosis they are equally useful. 
Twenty-two ATRs reacted exclusively with ZIKV sera (Figs 4 and 5, classes I and II), 13 exclusively with FlaviMix 
(classes IV and V) and 33 with both FlaviMix and at least one ZIKV pool (class III). Sequences of correspond-
ing stretches of polypeptide chain are compiled in Supplementary Tables S2 and S3. Alignments and sequence 
comparisons prompted sub-division of the ZIKV-exclusive and the FlaviMix-exclusive sets as explicated in detail 
below. Note that with “exclusive” we merely describe an observation in the present assay – in contrast to “specific” 
as an intrinsic property of a given antibody target.
Strings of amino acid residues displaying exclusive immunochemical reactivity towards ZIKV sera would 
be expected to differ substantially between ZIKV and the respective homologous sites of viruses making up the 
FlaviMix pool. This was true for 13 of 22 cases (class I, Supplementary Table S2, Fig. 5). Class I cases (such as 
ATR #2062, listed in Table 1) are characterized by a low to intermediate level of sequence identity between ZIKV 
and other flaviviruses across the respective antigen (NS4 in the case of ATR #2062) and a similarly low or lower 
degree of identity within the actual target region under consideration. The 13 class I ATRs are distributed among 
all ZIKV antigens – with the exception of antigens C and NS3 (Fig. 3). For the remaining nine cases (class II), 
sequence identity across the entire length of the respective antigen is low to intermediate but within the target 
region it is high between either ZIKV and all viruses of the FlaviMix pool (class IIa, five cases, represented in 
Table 1 by ATR #388) or ZIKV and the various Dengue subtypes only (class IIb, four cases, represented in Table 1 
by ATR #2029).
There are thirteen ATRs reacting exclusively with the FlaviMix pool. Five of these (class IV: #718, #1024, 
#1618, #2836, #3325, Supplementary Table S3) show strong similarity or identity with the respective homologous 
sites in ZIKV. Eight cases of FlaviMix-exclusive responses remain unexplained (class V: ATRs #25, #103, #1441, 
#1585, #1741, #1969, #2308, #2791, Supplementary Table S1). Anyhow, class V ATRs lack relevance to the present 
problem as they will not make any contribution to the development of a practical serological test.
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Discussion
This work marks the entry into a systematic and comprehensive search for antibody targets (epitopes, ATRs) of 
ZIKV in relation to those of other flaviviruses with the aim of identifying diagnostically useful antigenic sites 
eliciting ZIKV-specific antibodies. Despite the limited number of sera available for our analyses, some remarkable 
reactivity patterns emerged.
Antibody targets reacting with ZIKV sera pools exclusively. Among the 68 ATRs, 22 (summarized 
in Supplementary Table S2) reacted exclusively with one or more ZIKV sera pools, 13 recognized by IgM and 9 
by IgG with no overlap of the two sets. This lack of overlap is surprising in view of the fact that the combined 
processes of affinity maturation and class-switching do not qualitatively change the antigen recognition proper-
ties of an antibody: In a notional, infinitely large collection of ZIKV-positive sera, all antibody targets should be 
represented in both the IgM and the IgG set.
High local sequence conservation of an antigenic site across various virus species immediately suggests 
cross-reactivity. As cross-reactivity was missing in some cases, an explanation could, in principle, be offered 
by different antigenicity of the same stretch of polypeptide chain in homologous antigens due to different local 
three-dimensional structure (high for ZIKV, low for other flaviviruses). Some differences of 3D-structure have 
indeed been observed among different flaviviruses26.
Taken together, the findings corroborate the validity of the rationale underlying this study and the thirteen 
class I ATRs are the first bona fide candidates for being truly ZIKV-specific as required for serologically diagnos-
ing ZIKV infection against a dense background of cross-reactivity with other flaviviruses.
Cross-reacting antibody targets. Expectations that close serological scrutiny would reveal extensive 
cross-reactivity between ZIKV and other flaviviruses were borne out: At least 33 of the 68 ATRs identified in 
ZIKV and FlaviMix cross-react. As argued below, the real number is probably as high as 47 (Fig. 5). All ZIKV 
antigens carry a multitude of ATRs eliciting cross-reacting antibodies (Fig. 3) – a serious handicap for any sero-
logical ZIKV assay resting on whole antigens. Nevertheless, at least one attempt based on whole NS1 antigens 
of ZIKV and DENV (three cross-reacting ATRs by our count) has been made employing a combination of tests 
and quantitative signal comparison23. Prekumar et al. alleviate the cross-reactivity problem by focussing on 
two isolated domains of the ZIKV envelope protein that combine pronounced antigenicity with low sequence 
Figure 1. The ZIKV peptide microarray chip. (Panel A) Layout: Each chip hosts three identical arrays, each of 
which encompasses 1643 pentadekapeptides: 1136 covering the complete ZIKV Africa (AAV34151) polyprotein 
with an overlap of consecutive individual peptides of 12 amino acid residues plus 507 pentadekapeptides 
accommodating divergent sequences present in other ZIKV isolates (Brazil, USA, Senegal, French Polynesia). 
In addition, there are 96 biotin spots (green), which serve as internal positive controls and as markers of array 
boundaries (ref.23). (Panel B) Identification of positive signals: The criterion for a positive response is bright red 
fluorescence spread evenly across the entire spot area (examples marked by a blue circle).
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similarity between ZIKV and DENV22. Lastly, a competition ELISA based on a ZIKV-specific monoclonal 
anti-NS1 antibody has shown remarkable selectivity and specificity21. The assay, however, is bound to miss detect-
ing ZIKV-infections of individuals that happened not to produce antibodies against that one particular epitope.
experimental results compared with epitope prediction. Two studies have been published that aim 
at predicting B cell epitopes of ZIKV envelope proteins on the basis of theoretical considerations and homology 
to other flaviviruses27,28. Our experiments confirm 18 of these predictions and uncovered 37 additional targets 
(classes I to III, Fig. 5), not only in non-envelope proteins. On the other hand, 28 predictions could not be verified 
Figure 2. Original screening data (examples). Array spots showing positive reaction are boxed in. White boxes: 
Responses seen with FlaviMix pool (either exclusive or in combination with one or several ZIKV serum pools). 
Blue boxes: Responses seen only with ZIKV serum pools (“ZIKV-exclusives”). ATR numbers are stated next to 
corresponding boxes (Fig. 3). For experimental details refer to Materials and Methods.
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experimentally. This, however, does not necessarily indicate failed predictions but could alternatively be due, as in 
cases mentioned above, to a still incomplete collection of experimental targets. For a comprehensive comparison 
of prediction and experiment refer to Supplementary Table S4.
Non-saturating sampling of antibody targets. The notion of incomplete experimental representation 
of ZIKV ATRs in a limited number of human sera turned up in several different contexts. These are as follows. 
(i) Nine ATRs (class II) responded only to ZIKV sera despite their occurrence in homologous FlaviMix antigens 
with identical or very similar sequences. (ii) Reciprocally: Five ATRs of high sequence similarity between ZIKV 
and other flaviviruses (class IV) reacted exclusively with the FlaviMix pool. (iii) Among the 22 ZIKV-exclusive 
responses there is no overlap between ATRs recognized by the IgM and the IgG set of antibodies. (iv) Only a sub-
set of epitopes, previously predicted on theoretical grounds27,28, could be verified (so far) experimentally.
For every individual one of these four independent observations, incomplete ATR sampling offers an only 
tentative explanation; the notion, however, gains cogency by giving all of them a common, unified underpinning. 
As a corollary, two predictions follow: (a) Very likely, class II and class IV ATRs are true cross-reactors (Fig. 5). In 
contrast, there is no reason a priori to doubt the ZIKV specificity of the 13 members of class I. (b) A fair number 
of ZIKV ATRs are still to be discovered. This may turn out to be of practical importance in the eventual compila-
tion of a larger set of ZIKV-specific ATRs.
Conclusion and outlook
Specific serological identification of ZIKV against a background of cross-reacting other flaviviruses requires use 
of ZIKV-specific antibody targets. Since, in principle, any single target is represented in an individual B cell 
response with a probability of less than one, high sensitivity standards can only be met by the combined applica-
tion of several targets in parallel – each characterized by highest possible antigenicity. In that sense, substantial 
headway towards the development of a ZIKV-specific diagnostic assay has been made with the discovery of 13 
bona fide ZIKV-specific ATRs as reported here.
The remaining agenda en route to a practical diagnostic procedure such as ELISA, line assay, or bead 
flow-through assay is as follows. (i) Still other potentially cross-reacting flaviviruses (e.g. Japanese encephalitis 
and spondweni viruses) need to be included. (ii) The assignment of the 13 ATRs in class I as ZIKV-specific needs 
to be further consolidated. (iii) Additional specific ATRs should be found and ranked with respect to their anti-
genicity (i.e. signal frequency in a set of test sera).
All of the above points can be addressed in a straightforward manner, larger numbers of sera being the only 
prerequisite lying outside the scope of the present study. The approach builds upon antigen amino acid sequence as 
the only indispensable knowledge and it is not limited to addressing the cross-reactivity problem of flaviviruses only.
Beyond diagnosis, peptide microarray-based, high resolution serology may contribute to gaining a better 
understanding of a number of infection-connected problems. Antibody-mediated virus enhancement, for exam-
ple, is a well-documented phenomenon associated with flaviviruses and epidemiological studies linked Zika 
Figure 3. Mapping ATRs to ZIKV polyprotein. The horizontal bar represents the 3419 residue long 
unprocessed translation product of the ZIKV genome (Genbank accession number AAV34151). Marks along 
the grey line are spaced in intervals of 500 amino acid residues. ATRs are named by the number of their residue 
lying most closely to the N-terminus (Supplementary Table S1). ATRs marked black (class I ATRs, Fig. 5 and 
Supplementary Table S2) exclusively reacted with one or more ZIKV pools. ATRs marked grey reacted with 
FlaviMix pool and with zero to three ZIKV pools.
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outbreaks to increased incidence of Guillain-Barré syndrome, a neurological autoimmune condition known to 
interact with humoral immunity29.
Materials and Methods
serum samples and ethics statement. Samples of 42 well-characterized sera were provided by reference 
laboratories from Germany (Bernhard Nocht Institute, Hamburg), Senegal (Institut Pasteur de Dakar) and Brazil 
(University of São Paulo). The FlaviMix sera pool consists of 7 sera directed against dengue 1–4, yellow fever, tick-
borne encephalitis and West Nile viruses. The EU pool comprises 9 anti-ZIKV sera from EU travellers returning 
from Brazil. The Africa pool encompasses 19 anti-ZIKV sera from patients living in Senegal and Cape Verde. The 
Figure 4. Workflow of the study.
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Brazilian pool contains 7 anti-ZIKV sera from patients diagnosed at the University of São Paulo. All sera were 
either reference sera from the WHO collaboration center (Institut Pasteur de Dakar) or collected from patients 
during routine medical examinations or surveillance. All samples were collected between 5 to 28 days post onset 
of fever from patients tested positive with real-time PCR to the respective virus during the acute phase (>5 days). 
Samples which reacted positive to more than one virus were excluded from the study. Patients had given consent 
according to national and international ethical regulations. All samples were handled anonymously.
ZIKV peptide microarray scanning chips. The ZIKV proteome of the African strain is made up of seven 
antigens (prM not counted as a separate module) with a cumulative length of 3419 amino acid residues30. Antigen 
sequences were broken up into 1136 pentdecapeptides with a consecutive overlap of 12 residues representing the 
ZIKV African strain (GenBank accession number AAV34151). These were synthesized via SPOT synthesis31, passed 
through the SC2 process32 and spotted onto glass microscope slides (AIMS Scientific Products GmbH, Berlin, 
Germany) as illustrated in Fig. 1A (upper part of each of three identical arrays displayed in Fig. 1A). Each of the 
(smaller) lower array parts accommodates 507 additional pentadecapeptides that cover sequence stretches differ-
ing from the reference sequence in other ZIKV strains (Brazil, ALU33341; USA, AOS90225; Senegal, AHL43504; 
French Polynesia, AHZ13508). In addition, 96 spots of a biotin/(β-alanine)2/cellulose conjugate were deposited on 
the chips as positive controls and for marking array boundaries. After staining, they light up green (Fig. 1A).
Chip screening procedure. In each individual experiment, a ZIKV microarray chip was washed with abso-
lute ethanol for 3 min, then three times for 3 min each with TBS (50 mM Tris base, 150 mM NaCl, HCl ad pH 
7.6). After incubation with blocking buffer (TBS, 2% casein, 0.1% Tween-20) overnight, the chip was washed 
with T-TBS (TBS, 0.1% Tween-20) for 3 min. Thereafter, 70 µl of any of the four serum pools, diluted 120-fold, 
were added onto the chip. The chip was incubated in a humidified chamber at 4 °C overnight. Thereafter, the chip 
was washed three times for 5 min each with T-TBS. To visualize the binding of primary antibodies, the following 
was added onto the chip: 60 µl of blocking buffer containing Cy3-conjugated mouse anti-biotin and Alexa Fluor 
647-conjugated goat antibody directed against either human IgG or human IgM (240-fold dilution of stock solu-
tions prepared according to instructions of the commercial supplier, Jackson Immunoresearch Laboratories, West 
Grove, PA, USA). The chip was kept in a humidified chamber at room temperature for 1.5 hours. Subsequently, 
the chip was washed twice for 5 min with T-TBS, three times with distilled water for 5 min each, and dried by 
dipping into acetonitrile for 10 sec before visualization with an Agilent DNA microarray scanner. Each serum 
pool was tested in triplicate (three individual chips, corresponding to nine arrays total). For unknown reasons, 
all four sera pools produced atypically high levels of background which precluded application of the previously 
developed, automated spot calling procedure25. Therefore, array patterns were visually inspected and positive 
responses were identified in two steps – with the burden of safeguarding against false positives laid predominantly 
on stringent selection in step 1: (i) Individual signals were called positive if they showed bright red fluorescence 
spread uniformly across the entire spot area (Fig. 1B). (ii) A spot was taken as indicating an antibody target, if it 
passed step 1 in at least two arrays of the same chip with at least two out of three separate chips.
sequence alignment. Bioinformatics: Experimentally determined ATRs were aligned to viral polyproteins 
using the pairwise alignment tool of the GENEIOUS program package (Biomatters Ltd, Auckland, New Zealand). 
Query sequences were composed of the respective ATR plus fifty amino acid residues each on both sides – all 
taken from the reference ZIKV strain (GenBank accession number: AAV34151).
Figure 5. Classification of 68 experimentally identified ATRs. Roman numerals: Name of class. Arabic 
numerals: Number of ATRs in respective class. Class I: ZIKV-exclusives with low similarity to homologous 
sequences of FlaviMix viruses (residue identity <80%). Class II: Same with high similarity (residue identity 
≥80%). IIa: Similarity present in sequences of all viruses making up FlaviMix pool. IIb: Same but similarity 
only observed for Dengue subtypes. Class III: ATRs eliciting antibodies responding to both ZIKV and FlaviMix 
sera pools. Class IV: FlaviMix-exclusives with high similarity between ZIKV and FlaviMix. Class V: FlaviMix-
exclusives with no clear-cut location on polyprotein map of any virus represented in FlaviMix. Numbers of cases 
are graphically represented as bar areas. For usage of the term “exclusive” refer to main text.
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ethical statement. No ethical approval was required as all sera were either reference sera from the WHO 
collaboration center (Institut Pasteur de Dakar) or collected from patients during routine medical examinations 
or surveillance. All samples were handled anonymously.
Data Availability
All data produced during this study were included in the manuscript. Original data files are available upon re-
quest to the corresponding author.
ATR and Class Virus (accession number)






Id (%) Antig. 
within Subgroup
ATR #2062 (NS4) 
[Class I: 13 members] 
IgM (e,a,B) IgG (e,a,b)
Zika (AAV34151, Africa) 100 DGTTNNTIMEDSVP-AEVWTKY 100 100
Zika (AOS90225, USA) 96.4 ..............-.....RH 100 96.5
Zika (ALU33341, Brazil) 96.4 ..............-.....RH 90.9 97.1
Zika (AHZ13508, Fr. Polynesia) 96.5 ..............-.....RH 90.9 96.6
Zika (AHL43504, Senegal) 99.0 ..............-....... 90.9 99.1
Dengue 1 (NP_059433) 55.5 (98.6) ..ER..QVL.ENMD-V.I...E 40.9 45.8 98.9
Dengue 2 (NP_056776) 55.5 (97.7) ..VK..Q.L.EN.E-V.I...E 50.0 49.3 98.1
Dengue 3 (YP_001621843) 56.2 (98.7) ..QR..Q.L.ENMD-V.I...E 45.5 47.0 98.1
Dengue 4 (NP_073286) 56.3 (98.3) T.ER..Q.L.ENME-V.I..RE 36.4 47.3 98.8
Yellow Fever (NP_041726) 46.6 (96.4) E.PEEHE.LN..GETVKCRAPG 22.7 34.4 96.3
West-Nile (YP_001527877) 57.3 (98.6) ..PRT...L..NNE-V..I..L 50.0 43.0 98.2
TBE (NP_043135) 41.5 (95.8) E.PEA.AVD.A.GDLVTFRSPN 22.7 29.5 96.1
ATR #388 (E) [Class 
IIa: 5 members] IgM 
(e,a,b) IgG (E,a,b)
Zika (AAV34151, Africa) 100 DRGWGNGCGLFGKGS 100 100
Zika (AOS90225, USA) 96.4 ............... 100 96.4
Zika (ALU33341, Brazil) 96.4 ............... 100 96.2
Zika (AHZ13508, Fr. Polynesia) 96.5 ............... 100 94.4
Zika (AHL43504, Senegal) 99.0 ............... 100 98.9
Dengue 1 (NP_059433) 55.5 (98.6) ............... 100 58.9 98.5
Dengue 2 (NP_056776) 55.5 (97.7) ..............G 93.3 54.5 98.0
Dengue 3 (YP_001621843) 56.2 (98.7) ............... 100 58.7 98.5
Dengue 4 (NP_073286) 56.3 (98.3) ..............G 93.3 56.7 98.3
Yellow Fever (NP_041726) 46.6 (96.4) ............... 100 43.3 96.9
West-Nile (YP_001527877) 57.3 (98.6) ............... 100 54.0 98.9
TBE (NP_043135) 41.5 (95.8) ......H........ 93.3 39.1 98.8
ATR #2029 (NS4) 
[Class IIb: 4 members] 
IgM (e,A,B) IgG (e,a,b)
Zika (AAV34151, Africa) 100 TFVELMKRGDLPVWL 100 100
Zika (AOS90225, USA) 96.4 ............... 100 96.5
Zika (ALU33341, Brazil) 96.4 ............... 100 97.1
Zika (AHZ13508, Fr. Polynesia) 96.5 ............... 100 96.6
Zika (AHL43504, Senegal) 99.0 ............... 100 99.1
Dengue 1 (NP_059433) 55.5 (98.6) ......R........ 93.3 45.8 98.9
Dengue 2 (NP_056776) 55.5 (97.7) ...D..R........ 86.7 49.3 98.1
Dengue 3 (YP_001621843) 56.2 (98.7) ......R........ 93.3 47.0 98.1
Dengue 4 (NP_073286) 56.3 (98.3) ......R........ 93.3 47.3 98.8
Yellow Fever (NP_041726) 46.6 (96.4) V.R..VRNC...... 60.0 34.4 96.3
West-Nile (YP_001527877) 57.3 (98.6) N.L..LRTA...... 60.0 43.0 98.2
TBE (NP_043135) 41.5 (95.8) H.RH.LTHC.FTP.. 33.3 29.5 96.1
Table 1. Properties of ZIKV-exclusive ATRs. Three ATRs exclusively responding to ZIKV sera are illustrated, 
one representative case of each class I, IIa and IIb (for classification refer to Fig. 5; a comprehensive compilation 
of all ZIKV-exclusive ATRs and their sequence characteristics is given in Supplementary Table S2). Id values, 
if not stated otherwise, denote % sequence identity with reference strain Zika (AAV34151, Africa) of genomic 
polyprotein, respective antigen and ATR as indicated in column headers. In addition, Id values indicating 
bandwidths of sequence variation within subgroups of non-ZIKV flaviviruses (polyprotein or individual 
antigen) are listed. These were derived as follows. (i) A consensus sequence was computed for each subgroup. 
(ii) For each member of the respective subgroup percent residue identity with the consensus sequence was 
calculated. (iii) The mean value of these was defined as “Id within subgroup”. Alignments were performed as 
described in Materials and Methods. Symbols for provenances of ZIKV-sera are as follows. E: EU pool, A: 
African pool, B: Brazilian pool. Capital letters (E, A, B) indicate positive signal observed with respective sera 
pool, while small letters (e, a, b) represent lack of reactivity with either IgM or IgG.
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